Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis.

Journal: Journal of the anus, rectum and colon
Published Date: May 25, 2018

Abstract

OBJECTIVES: Although the aetiology of pouchitis after restorative proctocolectomy in ulcerative colitis (UC) remains unknown, infliximab (IFX) is often effective for this condition. However, indicators and predictors of treatment efficacy remain unclear. In this study, the association between serum tumor necrosis factor-alpha (TNF-α) levels and refractory pouchitis was evaluated.

Authors

  • Motoi Uchino
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Hiroki Ikeuchi
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Toshihiro Bando
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Akihiro Hirata
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Teruhiro Chohno
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Hirofumi Sasaki
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Yuki Horio
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.
  • Shiro Nakamura
    Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals